Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adolescents 11-17 years of age inclusive who have given their written assent and whose parent or legal guardian has given written informed consent at the time of enrollment;~2. Available for all the visits scheduled in the study (i.e. not planning to leave the area before the end of the study period);~3. In good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator;~4. With a negative urine pregnancy test (for female subjects only).~Exclusion Criteria:~1. History of any meningococcal vaccine administration;~2. Current or previous, confirmed or suspected disease caused by N. meningitidis;~3. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;~4. Pregnancy or nursing (breastfeeding) mothers;~5. Female subjects who have not used or do not plan to use acceptable birth control measures, for the 2 months duration of the study;~6. Any serious chronic or progressive disease;~7. Family members and household members of research staff;~8. Any condition which in the opinion of the investigator may interfere with the evaluation of the study objectives;~9. Significant acute or chronic infection within the previous 7 days or fever within 3 days prior to enrolment;~10. Antibiotics within 6 days prior to enrollment;~11. Known or suspected impairment/alteration of the immune system, immunosuppressive therapy;~12. Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;~13. History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component;~14. Receipt of or intent to immunize with any other vaccine(s) within 30 days prior and throughout the study period;~15. Participation in another clinical trial within the last 90 days or planned for during study.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- rMenB (Type: EXPERIMENTAL): Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
- Placebo/MenACWY (Type: ACTIVE_COMPARATOR): Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).